Delving into the Latest Updates on Shanghai Gencells Therapeutics Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Skin and Musculoskeletal Diseases

TIL therapy

Fusion protein

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	11

Top 5 Drug Type	Count

TIL therapy	5
Fusion protein	5
Monoclonal antibody	1

Top 5 Target	Count

CXCRs(CXC chemokine receptor)	1
HLA x KCNJ	1
TIGIT(T cell immunoglobulin and ITIM domains)	1
Other immune checkpoint proteins	1
TGF-β1(Transforming growth factor beta 1)	1

主要目的： 1.评价 GC203 TIL 细胞疗法在晚期恶性实体瘤患者中的安全性和耐受性。次要目的： 1. 根据 RECIST1.1 及 iRECIST 标准初步评价 GC203 TIL 细胞疗法治疗晚期恶性实体瘤患者的疗效。 2. 评价 GC203 TIL 细胞疗法对人体外周血 TBNK 细胞亚型、细胞因子的影响。 3. 评价 GC203 TIL 细胞疗法对受试者生活质量的影响。探索性目的： 1. 评价 GC203 TIL 细胞疗法中，转基因细胞在体内的增殖、存活和消除情况； 2. 评价 GC203 TIL 细胞疗法对人体免疫细胞亚群、分型的影响； 3. 评价 GC203 TIL 细胞疗法对 TCR 序列的影响，分析 TCR 序列变化与预后可能的关系。

[Translation]

Main objectives: 1. To evaluate the safety and tolerability of GC203 TIL cell therapy in patients with advanced malignant solid tumors. Secondary objectives: 1. To preliminarily evaluate the efficacy of GC203 TIL cell therapy in the treatment of patients with advanced malignant solid tumors according to RECIST1.1 and iRECIST criteria. 2. To evaluate the effects of GC203 TIL cell therapy on human peripheral blood TBNK cell subtypes and cytokines. 3. To evaluate the effects of GC203 TIL cell therapy on the quality of life of subjects. Exploratory objectives: 1. To evaluate the proliferation, survival and elimination of transgenic cells in vivo in GC203 TIL cell therapy; 2. To evaluate the effects of GC203 TIL cell therapy on human immune cell subpopulations and typing; 3. To evaluate the effects of GC203 TIL cell therapy on TCR sequences and analyze the possible relationship between TCR sequence changes and prognosis.

Start Date30 May 2024

Sponsor / Collaborator

Shanghai Gencells Therapeutics Co., Ltd.

[+1]

NCT06375187

/ RecruitingPhase 1

A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors

A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors

Start Date29 May 2024

Sponsor / Collaborator

Shanghai Gencells Therapeutics Co., Ltd.

100 Clinical Results associated with Shanghai Gencells Therapeutics Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Gencells Therapeutics Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Gencells Therapeutics Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Gencells Therapeutics Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

6

1

Preclinical

Phase 1

3

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GC203 TIL(Shanghai Juncell Therapeutics)	Advanced Malignant Solid Neoplasm More	Phase 1
Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)	Advanced Malignant Solid Neoplasm More	Phase 1
Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)	Advanced Malignant Solid Neoplasm More	Early Phase 1
GC201 TIL(Shanghai Gencells Therapeutics)	Female Genital Neoplasms More	Early Phase 1
GC-204	Solid tumor More	Preclinical